Katherine L. Widdowson

Katherine L. Widdowson

Auto-generated profile, based on publicly available information

Katherine L. Widdowson

GlaxoSmithKline Pharmaceuticals, Collegeville, PA, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2007 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
YWYong-Hui Wang
Yong-Hui Wang
JBJakob Busch-Petersen
Jakob Busch-Petersen
FWFeng Wang
Feng Wang
LMLanping Ma
Lanping Ma
WFWei Fu
Wei Fu
KWKatherine L. Widdowson
Katherine L. Widdowson

24 March 2009 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DLDramane I. Lainé
Dramane I. Lainé
BMBrent McCleland
Brent McCleland
STSonia Thomas
Sonia Thomas
CNChristopher Neipp
Christopher Neipp
BUBrian Underwood
Brian Underwood
MSMichael Salmon
Michael Salmon

1 June 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
CJCharles Jakielaszek
Charles Jakielaszek
MHMohammad Hossain
Mohammad Hossain
LQLian Qian
Lian Qian
CFCindy Fishman
Cindy Fishman
KWKatherine Widdowson
Katherine Widdowson
KOKaren O’dwyer
Karen O’dwyer
Gepotidacin is a first-in-class triazaacenaphthylene antibacterial agent that selectively inhibits bacterial DNA gyrase and topoisomerase IV through a unique binding mode and has the potential to treat a number of bacterial diseases. Development of this new agent to treat pneumonic plague caused by Yersinia pestis depends on the U.S. Food and Drug Administration Animal Rule testing pathway, as testing in humans is not feasible. Here, preclinical studies were conducted in the African green monkey (AGM) inhalational model of pneumonic plague to test the efficacy of gepotidacin. AGMs infected with Y. pestis were dosed intravenously with gepotidacin (48, 36, or 28 milligrams/kilogram per day) for 10 days to provide a plasma concentration that would support a rationale for a 1000 mg twice or thrice daily intravenous dose in humans or saline as a control. The primary end point was AGM survival with predefined euthanasia criteria. Secondary end points included survival duration and bacterial clearance. Gepotidacin showed activity in vitro against diverse Y. pestis isolates including antibiotic-resistant strains. All control animals in the inhalational plague studies succumbed to plague and were blood culture and organ culture positive for Y. pestis . Gepotidacin provided a 75 to 100% survival benefit with all dose regimens. All surviving animals were blood culture and organ culture negative for Y. pestis . Our randomized, controlled efficacy trials in the AGM pneumonic plague nonhuman primate model together with the in vitro Y. pestis susceptibility data support the use of gepotidacin as a treatment for pneumonic plague caused by Y. pestis .

1 January 2001
Verified
Book Chapter
Closed access
PDF file
HSHenry M. Sarau
Henry M. Sarau
KWKatherine L. Widdowson
Katherine L. Widdowson
MPMichael R. Palovich
Michael R. Palovich
JWJohn R. White
John R. White
DUDavid C. Underwood/Surname
David C. Underwood/Surname
DGDon E. Griswold
Don E. Griswold